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Editorial on the Research Topic
Novel Biomarkers for Type 2 Diabetes
Diabetes Mellitus, commonly known as diabetes, is a complex metabolic disorder characterized
by hyperglycemia over a prolonged period. The prevalence of diabetes is spiraling globally with
an estimated 425 million adults having diabetes in 2017 and 629 million by 2045 (1). In the year
2017 alone, diabetes caused an estimated 4 million deaths and a global economic health related
expenditure of∼730 billion US$ (1). Diabetes, if untreated, may lead to a number of serious chronic
complications involving smaller vessels, i.e., microvascular complications, and larger vessels, i.e.,
macrovascular complications. The microvascular complications involve the kidney, with chronic
kidney disease (nephropathy) being the most prevalent cause of end-stage kidney disease globally,
and nerve damage (neuropathy) that increases the risk of diabetic foot ulcers and/or amputations,
the most expensive complication of diabetes. Furthermore, damage to eyes (retinopathy), may
lead to blindness. The most common cause of mortality in diabetes are, however, macrovascular
complications that include cardiovascular disease and stroke (1).
Albeit there are different forms of diabetes, Type 2 Diabetes (T2D) is the most common type
(∼90%) and is characterized by insulin resistance, i.e., the body’s inability to respond fully to
insulin, that may lead to decreased insulin production. T2D is an excellent example of a disease
in which the etiology is characterized by gene-environment interaction (GEI) where modern-day
sedentary lifestyle along with genetic susceptibility predisposes the individual to an increased risk
of developing diabetes. In the past decade, large scale genome wide association studies (GWAS)
(2) and GEI studies (3) laid the foundations for omics era by identifying hundreds of genetic
risk variants that in aggregate explain a substantial part of the heritability of T2D. More recently,
exome sequencing (4) and exome wide association studies (5, 6), enriched for missense and low
frequency variants, have discovered additional genes and pathways associated with risk for T2D and
its complications (7). We have recently identified a number of promising blood and urine-based
biomarkers of inflammatory, endothelial, and microbiome origin (8), for diabetic complications,
especially diabetic kidney disease (DKD) (9, 10). However, identifying biomarkers for T2D and
its complications remains challenging due to the heterogeneous nature of T2D. The heterogeneity
relates not only to glycemic control or treatment response (11), but also to clinical phenotypes
such as age of onset and body mass index, biochemical characteristics such as insulin resistance,
and differences in environmental exposures, which all lead to disease variability (12). Some recent
studies using data clustering methods have demonstrated that diabetes may be clustered into
smaller, somewhat homogenous subgroups using individual-level clinical, genetic and metabolic
data (13, 14), which suggests that there is need for developing stratified treatments. In line with
these observations, the current issue highlights recent research articles focusing on biomarkers for
type 2 diabetes and its complications.
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Winter et al. provide an overview of inflammatory markers
involved in the activation of innate and adaptive immune
systems that are recognized as key mediators for the development
and progression of renal damage in DKD. The authors
discuss a hypothesis whereby the activation of inflammatory
pathways leads to a state of chronic systemic inflammation
and diabetic complications, in particular atherosclerosis and
CVD, in individuals with T2D, and provide evidence on
the potential of anti-inflammatory therapies in reducing the
risk of diabetes complications. Winter et al. discusses cross
sectional data on acute phase proteins (C-reactive protein or
hsCRP and fibrinogen) and pro-inflammatory cytokines (IL-
6 and TNF-α) that associate with increased risk of T2D.
After adjustment for body mass index and adiposity traits, the
association between hsCRP and T2D is attenuated (Winter et al.).
This highlights adipose tissue-mediated low-grade inflammation
being associated with increased insulin resistance and T2D
development, especially in obese individuals (15). Obesity,
one of the major contributors to T2D pathogenesis, leads
to rapid fat cell expansion in both cell size and number,
with their oxygen demand exceeding the supply. This low-
oxygen state, hypoxia, leads to upregulation of the anti-hypoxic
protein HIF-1α, which in turn causes tissue inflammation
and prevents fat cells (adipocytes) from responding normally
to insulin (16, 17). A meta-analysis of GWAS on hsCRP
showed shared genes and pathways that are associated with
insulin resistance and T2D (18, 19), consistent with another
study identifying body fat percentage genes linking adiposity
and cardio-metabolic risk (20). Finally, Winter et al. discuss
the kidney’s vulnerability to complement-mediated injury,
and potential biomarker associations with different kidney
phenotypes (glomerulonephritis, tubulointerstitial injury, C3
glomerulopathy). Interestingly, the authors underscore the role
of leukocytes in renal complications and highlight neutrophil-
lymphocyte ratio as a potential biomarker for DKD.
Yim et al. report a blood-based biomarker nertrin-1, a
laminin-related protein whose levels are increased in individuals
with impaired fasting glucose (IFG) and T2D. Netrin 1 promotes
leukocyte migration in peripheral organs, tissue regeneration,
and modulation of inflammation, which may explain it relevant
to T2D as discussed above. Moreover, netrin-1 exhibits an
anti-angiogenic effect, allowing higher blood flow to hypoxic
tissue, and it has demonstrated cardio-protective effects by
preventing ischemia-reperfusion injury in animal studies (Yim
et al.). Although the study is interesting, observing positive
correlations between nertrin-1 and insulin resistance and T2D,
and a negative correlation with estimated glomerular filtration
rate (eGFR) (a proxy of kidney function measure), in cross-
sectional data, the authors underscore the need for longitudinal
studies and validation studies—a highly relevant consideration
for any biomarker study.
Vaishya et al. highlight the relevance of developing new
biomarkers—proteins, metabolites, MicroRNA or other
biomolecules—for T2D to complement traditional biomarkers
such as HbA1c and blood glucose. By definition, a biomarker is a
biomolecule/biological state that can be used for the prognosis,
diagnosis, and follow-up of the pathological state or the severity
of a disease. The current biomarkers used in the clinic (HbA1c,
plasma glucose etc.) are only useful after the manifestation of
the disease and fail to completely account for heterogeneity in
diabetes pathogenesis, insulin resistance and insulin production,
and thus do not guide toward the right choice of therapy. In
addition, there is a need for developing biomarkers to early
and precise prediction of diabetes complications. Thus, the
identification of more specific, stage-related, non-invasive
biomarkers with a greater accuracy in diagnosis and progression
of T2D is vital. The authors also discuss the relevance of emerging
biomarkers such as microRNAs, proteins and metabolites, listing
some of the most relevant biomarker candidates associated
with diabetes and its complications. The authors discuss very
important issues relating to improving individual risk assessment
methods with addition of multi-marker approaches and models
comprising longitudinal data points. Albeit classic GWAS and
recent metabolomics and proteomics approaches involving large
consortia or biobanks (3, 5, 21), are required for biomarker
discovery (6), more sophisticated modeling, longitudinal study
designs, and data integration approaches are essential for the
validation of these biomolecules as relevant biomarkers for T2D.
Recent studies have highlighted brain as a key player
in glucose regulation and the pathogenesis of metabolic
disorders such as T2D (22). Liang et al. propose that
chronic psychological stress plays an important role in T2D
pathogenesis and use microRNAs as biomarkers measuring
these surrogate phenotypes. There is evidence suggesting that
increased activation of hypothalamus-pituitary-adrenal (HPA)
axis and sympathetic nervous system (SNS), and consequent
elevation of stress hormones, may be important for the etiology
and development of T2D. Liang et al. explore the association
between neuroendocrine stress response-related circulating
miRNAs and T2D and identify a number of interesting
associations that may point toward potential biomarkers for
prediabetes and insulin resistance in adults.
Different omics platforms—genomics, metabolomics,
proteomics, and microbiomics—and RNA sequencing-based
studies, coupled to novel data science methods involving
bioinformatics, data mining, imaging, machine learning, neural
networks, are now revolutionizing biomarker development
(21, 23, 24). Specialized health care centers, diabetes clinics and
hospitals that manage patient-based registers longitudinally
and impart education to patients and health workers, have
already started effective collaborations with data scientists
and/or research field specialists to narrow the gap between
bio-banking, biomarker development, and biomarker validation
in intervention studies or clinical trials. Adopting such methods,
in accordance with data protection and ethical guidelines, with
emphasis on judicial use of follow up patient data is steadily
moving closer to effective personalized treatment (23) and
the building of efficient translational research facilities, which
promises to improve the quality of life for the patients and enable
better health care.
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